Published in Blood on September 07, 2006
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 9.68
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood (2007) 4.91
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell (2008) 2.71
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest (2008) 2.31
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med (2012) 2.08
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Differentiation therapy of leukemia: 3 decades of development. Blood (2009) 2.02
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood (2008) 1.87
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood (2015) 1.75
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem (2012) 1.74
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70
Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res (2011) 1.65
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer (2011) 1.65
Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett (2008) 1.53
Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol (2011) 1.47
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol (2009) 1.45
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.40
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res (2012) 1.39
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs (2008) 1.36
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res (2008) 1.36
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer (2009) 1.34
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone (2011) 1.30
Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia (2009) 1.27
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A (2008) 1.27
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (2015) 1.25
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol (2008) 1.25
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood (2011) 1.22
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat (2011) 1.18
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol (2010) 1.15
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res (2010) 1.14
Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol (2010) 1.10
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol (2012) 1.10
Novel pharmacologic treatment attenuates septic shock and improves long-term survival. Surgery (2013) 1.09
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica (2009) 1.08
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 1.08
Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med (2011) 1.07
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res (2009) 1.07
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol (2015) 1.06
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs (2010) 1.05
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood (2014) 1.03
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol (2010) 1.03
Management of indolent lymphoma: where are we now and where are we going. Blood Rev (2012) 1.02
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma (2010) 1.02
Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia (2010) 1.02
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol (2009) 1.01
Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One (2013) 1.01
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs (2010) 0.99
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer (2007) 0.98
Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol (2012) 0.98
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica (2010) 0.98
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol (2010) 0.96
Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol (2008) 0.96
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer (2010) 0.96
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol (2011) 0.95
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer (2014) 0.94
Targeting histone deacetylases for the treatment of disease. J Cell Mol Med (2008) 0.94
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat (2011) 0.93
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs (2010) 0.93
Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics (2010) 0.92
The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia (2013) 0.92
Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol (2008) 0.92
Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol (2011) 0.91
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol (2011) 0.90
The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One (2013) 0.90
Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model. Mol Pharm (2012) 0.90
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2015) 0.89
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell Death Differ (2013) 0.89
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med (1987) 3.13
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol (2001) 2.57
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (2001) 2.24
Histone acetylation and disease. Cell Mol Life Sci (2001) 2.11
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood (1997) 1.89
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol (2005) 1.71
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol (2001) 1.59
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol (2002) 1.54
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol (2005) 1.45
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia (2004) 1.44
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol (2006) 1.21
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma (2002) 1.13
Mycosis fungoides and the Sézary syndrome. Curr Opin Oncol (2004) 1.06
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res (2002) 1.04
Erythroderma: review of 82 cases. South Med J (1986) 1.03
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol (2005) 1.01
Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (2003) 0.98
Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl (2005) 0.94
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2003) 4.44
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.66
Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov (2009) 3.50
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Histone deacetylase inhibitors. Adv Cancer Res (2004) 2.93
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
Histone deacetylases. Curr Opin Pharmacol (2003) 2.58
Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol (2011) 2.48
Adult mouse brain gene expression patterns bear an embryologic imprint. Proc Natl Acad Sci U S A (2005) 2.46
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 2.26
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood (2003) 1.92
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol (2005) 1.91
Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci U S A (2003) 1.86
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther (2006) 1.84
Folic Acid-conjugated Graphene Oxide loaded with Photosensitizers for Targeting Photodynamic Therapy. Theranostics (2011) 1.83
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol (2005) 1.71
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res (2006) 1.71
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res (2004) 1.65
Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. Biomaterials (2011) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res (2009) 1.54
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs (2007) 1.53
Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev (2002) 1.51
Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials (2011) 1.50
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 1.46
Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies. BMC Med Genomics (2012) 1.45
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett (2011) 1.42
Breast cancer risk assessment: positive predictive value of family history as a predictor of risk. Menopause (2011) 1.41
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res (2009) 1.41
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res (2009) 1.40
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol (2004) 1.40
Effect of deodorant and antiperspirant use and presence or absence of axillary hair on absorption of testosterone 2% solution applied to men's axillae. J Sex Med (2014) 1.39
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther (2014) 1.37
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs (2008) 1.36
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res (2008) 1.33
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res (2007) 1.24
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res (2005) 1.23
A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing. Prenat Diagn (2013) 1.22
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood (2006) 1.22
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res (2010) 1.20
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res (2010) 1.19
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol (2009) 1.17
Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck (2007) 1.17
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther (2008) 1.15
Apoptosis, senescence, and autophagy in rat nucleus pulposus cells: Implications for diabetic intervertebral disc degeneration. J Orthop Res (2012) 1.14
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 1.13
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci (2009) 1.12
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer (2012) 1.12
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des (2012) 1.12
Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. J Sex Med (2011) 1.11
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res (2002) 1.10
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood (2008) 1.09
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood (2013) 1.09
Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res (2005) 1.06
A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett (2012) 1.06
HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs (2003) 1.05
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood (2002) 1.05
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res (2002) 1.04
A CCD-based reader combined quantum dots-labeled lateral flow strips for ultrasensitive quantitative detection of anti-HBs antibody. J Biomed Nanotechnol (2012) 1.02
Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol (2010) 1.01
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem (2012) 1.01
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol (2009) 1.01
Photosensitizer-conjugated silica-coated gold nanoclusters for fluorescence imaging-guided photodynamic therapy. Biomaterials (2013) 1.00
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res (2003) 0.99
Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp (2004) 0.99
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol (2003) 0.99
Protein-directed one-pot synthesis of Ag microspheres with good biocompatibility and enhancement of radiation effects on gastric cancer cells. Nanoscale (2011) 0.99
BRCAA1 monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer. J Nanobiotechnology (2011) 0.98